Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TKD activated natural killer cells - Alphageneron Pharmaceuticals/multimmune

Next Previous
Drug Profile

TKD activated natural killer cells - Alphageneron Pharmaceuticals/multimmune

Alternative Names: Activated autologous NK cells - multimmune; Enkastim-ev; Enkastim-iv; Heat shock protein 70 peptide activated natural killer cells; HSP70 peptide activated natural killer cells; Hsp70-peptide TKD/IL-2 activated, autologous NK cells; Natural killer cell therapy - multimmune

Latest Information Update: 10 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator multimmune
  • Developer Alphageneron Pharmaceuticals; multimmune; Technical University Munich
  • Class Antineoplastics; Cell therapies; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • No development reported Colorectal cancer

Most Recent Events

  • 10 Apr 2024 Preclinical trials in Non-small cell lung cancer in USA (IV) (Alphageneron Pharmaceuticals Pipeline, April 2024)
  • 10 Apr 2024 Alphageneron Pharmaceuticals plans a phase I trial for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Combination therapy) in future (Alphageneron Pharmaceuticals Pipeline, April 2024)
  • 18 Oct 2021 Alphageneron Pharmaceuticals plans phase II trial in Non-small cell lung cancer (Late-stage disease) in 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top